{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.50","value":"-11.7"},{"groupId":"OG001","spread":"11.04","value":"-13.6"},{"groupId":"OG002","spread":"11.51","value":"-15.6"},{"groupId":"OG003","spread":"11.46","value":"-16.2"},{"groupId":"OG004","spread":"11.48","value":"-16.2"},{"groupId":"OG005","spread":"11.26","value":"-16.5"}]}],"title":"Swollen Joint Count (SJC)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.82","value":"-17.4"},{"groupId":"OG001","spread":"15.12","value":"-20.3"},{"groupId":"OG002","spread":"15.82","value":"-23.1"},{"groupId":"OG003","spread":"16.14","value":"-23.8"},{"groupId":"OG004","spread":"15.89","value":"-23.8"},{"groupId":"OG005","spread":"16.37","value":"-24.8"}]}],"title":"Tender Joint Count (TJC)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"532"},{"groupId":"OG001","value":"506"},{"groupId":"OG002","value":"454"},{"groupId":"OG003","value":"422"},{"groupId":"OG004","value":"405"},{"groupId":"OG005","value":"371"}],"units":"Participants"}],"description":"Swollen joint count (SJC) includes an assessment of 66 joints, and tender joint count (TJC) include an assessment of 68 joints. Joint prosthesis, arthrodesis or fused joints were not considered. Joints were assessed and classified as swollen/not swollen, and tender/not tender, by pressure and joint manipulation on physical examination. Change from Baseline in the SJC and TJC were calculated at given time points, and a negative change indicates improvement.\n\nA small proportion of participants in the all-exposure population reduced or stopped their oral corticosteroid use due to sustained efficacy (defined as at least a 50% improvement in both swollen joint count (SJC) and tender joint count (TJC).","dispersionType":"Standard Deviation","groups":[{"description":"Participants with scores at 24 weeks post-baseline.","id":"OG000","title":"Week 24"},{"description":"Participants with scores at 48 weeks post-baseline.","id":"OG001","title":"Week 48"},{"description":"Participants with scores at 108 weeks post-baseline.","id":"OG002","title":"Week 108"},{"description":"Participants with scores at 156 weeks post-baseline.","id":"OG003","title":"Week 156"},{"description":"Participants with scores at 204 weeks post-baseline.","id":"OG004","title":"Week 204"},{"description":"Participants with scores at 264 weeks post-baseline.","id":"OG005","title":"Week 264"}],"paramType":"MEAN","populationDescription":"All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.","reportingStatus":"POSTED","timeFrame":"through 264 Weeks","title":"Change From Baseline in Scores for Swollen and Tender Joint Counts Over Time, Through 264 Weeks","type":"SECONDARY","unitOfMeasure":"Joints"}